News

Criteo Insider Trading and Recent Company Developments

Criteo Insider Trading and Recent Company Developments

Criteo Executive Sells Significant Shares

Criteo S.A. (NASDAQ: CRTO) has seen a noteworthy insider trading occurrence involving Chief Legal Officer Damon Ryan. As per updated filings with the SEC, on September 12, Ryan sold 16,845 ordinary shares of Criteo. The sale occurred at prices between $44.24 and $44.52, totaling over $747,412. With an average price of $44.37 per share, this transaction highlights Criteo's strong stock performance in the market.

Details on Option Exercises

In addition to the share sale, it was reported that Ryan also exercised options to purchase the same number of shares at $20.66 each, resulting in an added investment of $348,017. These options were part of a grant from 2018 and followed an annual vesting schedule with quarterly vesting over 36 months, contingent on his ongoing employment.

Why Insider Trading Matters

For many investors, insider trading gives valuable insight into a company's future prospects, reflecting the confidence that its leadership has in its direction. Ryan's recent transactions illustrate a strategy to capitalize on gains from stock options previously granted to him, a typical move among corporate executives looking to monetize their equity compensation.

Criteo’s Business Landscape

Criteo is a key player in the advertising technology field, focusing on providing advertising solutions to various clients. The company has experienced significant stock price fluctuations, which can bring both challenges and opportunities for investors. Each ordinary share corresponds to one American Depositary Share, where one share equals one ordinary share of Criteo S.A.

If you want detailed ownership and transaction information, Criteo's latest definitive proxy statement filed with the SEC offers further insights into the equity interests of Damon Ryan and other key stakeholders.

Recent Developments and Leadership Changes

The recent trading activities of Criteo’s Chief Legal Officer coincide with crucial developments within the company. CEO Megan Clarken has announced her retirement plans within the next year, sparking efforts to find her successor. This revelation follows a robust performance in Q2, where Criteo proudly reported a revenue of $471 million and an adjusted EBITDA of $93 million, marking the third consecutive quarter of impressive double-digit organic growth.

Analyst Upgrades Boost Market Confidence

With these positive results, institutional players like DA Davidson have upgraded Criteo's rating from `Neutral` to `Buy`, setting a new price target of $58.00. At the same time, BMO Capital Markets continues to endorse an `Outperform` rating, raising its price target to $55.00. Both firms express strong confidence in Criteo’s strategic path and overall future prospects.

Understanding Criteo's Financial Health

As Criteo S.A. (NASDAQ: CRTO) continues its successful market journey, investors are eager to grasp its financial health. Recent analyses indicate that Criteo holds a market capitalization of $2.44 billion, with a Price/Earnings (P/E) ratio currently at 19.94, based on the last twelve months leading up to Q2 2024. These metrics help investors determine Criteo's valuation compared to its earnings.

Assessing Criteo’s Growth Potential

Moreover, the company's PEG ratio is notably low at 0.02, pointing to the possibility that Criteo's earnings growth is overlooked relative to its current valuation. The stock has achieved a commendable 21.14% total return over the past three months, indicating a rise in investor confidence—often reflected in management’s share buyback initiatives, indicating their belief in the undervaluation of shares. Additionally, Criteo's balance sheet displays a solid cash position, indicating they have more cash than outstanding debt, which suggests robust financial stability.

Final Thoughts for Investors

As analysts update their earnings forecasts for Criteo, the company's profitability outlook looks increasingly bright. These insights and various key metrics are essential for investors considering their stakes in Criteo. Continuous information released through channels like investor presentations allows for a better understanding of Criteo's market position and future trajectory.

Frequently Asked Questions

What was the total amount garnered from Damon Ryan's share sale?

Damon Ryan sold 16,845 shares for over $747,412.

How does insider trading impact investor decisions?

Insider trading provides insights into executive confidence and company performance, influencing investor sentiment.

What recent performance indicators highlight Criteo's status?

Criteo reported strong revenue and EBITDA figures, alongside sustaining double-digit organic growth.

Why is the PEG ratio significant for Criteo?

A low PEG ratio indicates potential undervaluation in relation to earnings growth expectations.

What are the recent ratings upgrades for Criteo?

DA Davidson upgraded Criteo's rating to 'Buy', with BMO Capital maintaining an 'Outperform' rating.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Synova Global Taps Eventus for Top Trade Surveillance

Updated Category News Views 144

Synova and Eventus: A Powerful Partnership If you've ever traded a share or two, you know the name of the game is risk management. Step into Synova Global's latest move, and you'll see a gamble worth watching closely. This time around, Synova has tapped Eventus to bring their Validus trade surveillance platform into the fold. Now, Eventus and its star player, Validus,...

Continue Reading
Cambiotics Launches Key Trial on Reducing PFAS in Firefighters

Updated Category News Views 44

Pioneering Efforts to Combat 'Forever Chemicals' Cambiotics is stepping into some uncharted territory—tackling the tricky problem of PFAS accumulation in firefighters. If you’ve been following this, PFAS, or per- and polyfluoroalkyl substances, have been living rent-free in our bodies for years. Used in firefighting equipment and foams, these chemicals stick around,...

Continue Reading
ZBS Group Takes Over Rabinowitz’s CPA Practice with Bold Moves

Updated Category News Views 44

Transitioning Power in the CPA World Let's cut to the chase—when a seasoned CPA like Joseph Rabinowitz picks up the phone to secure a succession partner, it's a big deal. Enter ZBS Group LLP, steered by Michael Zaidman, which isn't a stranger to these waters, undertaking their fourth CPA practice acquisition through Rabinowitz's corner of the accounting universe....

Continue Reading
Connecting NIH Data: Transforming Scientific Discoveries

Updated Category News Views 44

Rethinking How Research Data Drives Discovery When researchers generate truckloads of data, finding patterns that lead to breakthroughs often becomes a game of hide and seek. It's like having a jumbo puzzle with pieces scattered all over the place. Enter the NIH Common Fund Data Ecosystem—a game changer attempting to glue together these pieces across the research...

Continue Reading
Cerbo's AI Scribe Expands to Telehealth Success

Updated Category News Views 46

Cerbo Enhances Telehealth With AI Scribe Expansion The digital healthcare playground looks like it's getting a nudge toward efficiency with Cerbo's latest move. Just when you thought telehealth couldn't get much sharper, these folks have drawn a line in the sand with their AI Scribe, which now makes its presence felt in virtual visits. No more juggling a dozen screens...

Continue Reading
SportsMed Expands to 58 Clinics, New Opening in Jersey City

Updated Category News Views 28

SportsMed Physical Therapy Expands with New Clinic Well, here we are, talking about expansion. And not just any expansion—I'm talking about SportsMed Physical Therapy flexing its muscles in Jersey City Heights, boosting their count to 58 clinics scattered across New Jersey and Connecticut. It's like watching a network of care roots spreading deeper into the region, and...

Continue Reading
Geopolitical Talks Shake Oil Market, Refine Stocks' Path

Updated Category News Views 92

Diplomacy Takes Center Stage So here we are again, riding the rollercoaster of geopolitics that's jerking the oil market around like a marionette. With the U.S. and Iran allegedly chatting—mind you, with a ton of smoke and mirrors through Qatar and Islamabad—every trader's watching, hoping for a ceasefire that might either stabilize or further jolt energy prices. Oil...

Continue Reading
Linker Vision's AI Platform Boosts Urban Planning

Updated Category News Views 72

Now, I've seen a fair share of tech rollouts claiming to change the world, but Linker Vision’s new AI platform, Linker AI Nexa, might actually be onto something real here. Revealed at the Smart City Expo World Congress 2026 in Barcelona, this isn't just another pretty interface—it’s packing some serious firepower with NVIDIA tech. Bringing Physical AI to City...

Continue Reading
Bright Minds Faces Legal Scrutiny Over FDA Trial Hold

Updated Category News Views 72

Bright Minds Biosciences Under the Microscope Well, it looks like Bright Minds Biosciences has found itself in some hot water with investors. After the FDA put a partial hold on their Phase 2 trial for BMB-101, designed for epilepsy treatment, the stock took a nosedive. If you're holding a piece of NASDAQ:DRUG, or even if you cut your losses and ran, it's time to tune in....

Continue Reading
Instanodes Tackling Quantum Threats in Blockchain

Updated Category News Views 114

Diving Into Quantum Cryptography for Blockchain Instanodes is throwing down the gauntlet for the blockchain crowd as the field of quantum computing edges ever closer to unsettling the cryptographic order. This company's latest play? Post-quantum account engineering for major players like Ethereum and Solana. And it's not just tinkering—they're giving the status quo a...

Continue Reading

Top 5 Most Recently Viewed Articles

MindMaze Therapeutics: 2026 Business Update and Insights

Updated Category News Views 16

Breaking Down MindMaze’s 2026 Update Today, I’m sifting through MindMaze Therapeutics' latest half-year report like a prospector panning for gold nuggets. It’s a mixed bag, folks, full of expansion optimism underlined by a nagging loss in the financial ledger. But they say fortune favors the bold, right? The company has ambitious ideas, and their genetic makeup...

Continue Reading
Tantrum Sportfishing Celebrates Record Blue Marlin Achievement

Updated Category News Views 190

Historic Milestone for Tantrum Sportfishing In an inspiring turn of events for the sportfishing community, Tantrum Sportfishing has achieved a remarkable milestone. The Kona-based charter company announced its proud entry into the illustrious "Grander Club" after landing a colossal 1,039-pound Blue Marlin. This catch not only signifies a personal triumph for the team but...

Continue Reading
New Bitcoin ETF Offers Investors Unique Downside Protection

Updated Category News Views 227

Calamos Introduces a Groundbreaking Bitcoin ETF Investment management firm Calamos is excited to roll out an innovative approach to cryptocurrency investing with the launch of the world’s first 100% downside-protected Bitcoin exchange-traded fund (ETF). This launch comes just after an announcement suggesting that an ETF will be available for investors looking to...

Continue Reading
Exciting Developments in dsm-firmenich's Share Repurchase Initiative

Updated Category News Views 178

Progress Update on dsm-firmenich's Share Repurchase Program dsm-firmenich, known for its innovative approach in the fields of nutrition, health, and beauty, is actively implementing its large-scale share repurchase program. This initiative began earlier this year and signifies a strategic move to enhance shareholder value and manage capital effectively. Initial...

Continue Reading
Capricor Therapeutics: Key Deadlines for Shareholders to Remember

Updated Category News Views 133

Crucial Dates for Capricor Therapeutics Shareholders The Gross Law Firm has released an important notice for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm encourages anyone who purchased shares during the specified class period to connect with them regarding possible lead plaintiff appointments. Being appointed as the lead plaintiff isn't necessary...

Continue Reading